FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Nun	nber: I average bui	3235-028
Estimated	l average bui	rden
hours ner	reenonce.	0.1

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*					2. Issuer Name and Ticker or Trading Symbol CATALYST PHARMACEUTICALS, INC. [5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
MCENANY PATRICK J				CPRX]						Director	•	10% Owner		ner			
(Last)	(F	irst)	(Middle)	╌┝									Officer (below)	(give title		Other (spelow)	pecify
355 ALHAMBRA CIRCLE, SUITE 801					3. Date of Earliest Transaction (Month/Day/Year) 12/28/2021						President and CEO						
(Street)	. F	r	33134	4.	. If Ame	endment, [Date o	f Original Fil	ed (M	Ionth/Da	y/Year)	Line	•	•	•		icable
GABLES	5	L	33134											ed by One I			
(City)	(S	tate)	(Zip)									Form filed by More than One Reporting Person					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3) 2. Transa Date (Month/D			e	action 2A. Deemed Execution Date, if any (Month/Day/Year)		e, Transaction Disposed Code (Instr.		ities Acquired (A) or d Of (D) (Instr. 3, 4 and 5		Beneficially Owned Following		Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
							Code	/ A	Amount (A) or (D)		r Price	Reported Transacti (Instr. 3 a	on(s)			nstr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amour of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio	Owi For Dire or li (I) (I	nership m: ect (D) ndirect nstr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
_				Code	v	(A)	(D)	Date Exercisable		oiration e	Title	Amount or Number of Shares		(Instr. 4)	.,(3)		
Options to purchase common stock	\$7.07	12/28/2021		A		270,000		(1)	12/2	28/2028	Common Stock	270,000	\$0	3,490,83	14	D	

Explanation of Responses:

1. Options vest in equal tranches, 1/3rd on December 28, 2022, 1/3rd on December 28, 2023 and 1/3rd on December 28, 2024.

/s/ Patrick J. McEnany

12/30/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.